256 related articles for article (PubMed ID: 30194451)
1. A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.
Stylianou N; Lehman ML; Wang C; Fard AT; Rockstroh A; Fazli L; Jovanovic L; Ward M; Sadowski MC; Kashyap AS; Buttyan R; Gleave ME; Westbrook TF; Williams ED; Gunter JH; Nelson CC; Hollier BG
Oncogene; 2019 Feb; 38(7):913-934. PubMed ID: 30194451
[TBL] [Abstract][Full Text] [Related]
2. FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer.
Børretzen A; Gravdal K; Haukaas SA; Beisland C; Akslen LA; Halvorsen OJ
J Pathol Clin Res; 2019 Oct; 5(4):272-286. PubMed ID: 31464093
[TBL] [Abstract][Full Text] [Related]
3. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
[TBL] [Abstract][Full Text] [Related]
4. Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression.
Hu J; Tian J; Zhu S; Sun L; Yu J; Tian H; Dong Q; Luo Q; Jiang N; Niu Y; Shang Z
Br J Cancer; 2018 Jan; 118(1):88-97. PubMed ID: 29123266
[TBL] [Abstract][Full Text] [Related]
5. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
[TBL] [Abstract][Full Text] [Related]
6. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
Colditz J; Rupf B; Maiwald C; Baniahmad A
Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics.
Chaves LP; Melo CM; Saggioro FP; Reis RBD; Squire JA
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946849
[TBL] [Abstract][Full Text] [Related]
8. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
Lindsay CR; Le Moulec S; Billiot F; Loriot Y; Ngo-Camus M; Vielh P; Fizazi K; Massard C; Farace F
BMC Cancer; 2016 Feb; 16():168. PubMed ID: 26923772
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
10. Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells.
Yang M; Ma B; Shao H; Clark AM; Wells A
BMC Cancer; 2016 Jul; 16():419. PubMed ID: 27387344
[TBL] [Abstract][Full Text] [Related]
11. Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.
Haider M; Zhang X; Coleman I; Ericson N; True LD; Lam HM; Brown LG; Ketchanji M; Nghiem B; Lakely B; Coleman R; Montgomery B; Lange PH; Roudier M; Higano CS; Bielas JH; Nelson PS; Vessella RL; Morrissey C
Clin Exp Metastasis; 2016 Mar; 33(3):239-48. PubMed ID: 26667932
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
13. OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Qi XK; Han HQ; Zhang HJ; Xu M; Li L; Chen L; Xiang T; Feng QS; Kang T; Qian CN; Cai MY; Tao Q; Zeng YX; Feng L
Theranostics; 2018; 8(8):2202-2216. PubMed ID: 29721073
[No Abstract] [Full Text] [Related]
14. Epithelial-to-mesenchymal transition in tumor progression.
Prieto-García E; Díaz-García CV; García-Ruiz I; Agulló-Ortuño MT
Med Oncol; 2017 Jul; 34(7):122. PubMed ID: 28560682
[TBL] [Abstract][Full Text] [Related]
15. Achieving resistance specificity in prostate cancer.
Wadhwa B; Dumbre R
Chem Biol Interact; 2016 Dec; 260():243-247. PubMed ID: 27720870
[TBL] [Abstract][Full Text] [Related]
16. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.
Tse BWC; Volpert M; Ratther E; Stylianou N; Nouri M; McGowan K; Lehman ML; McPherson SJ; Roshan-Moniri M; Butler MS; Caradec J; Gregory-Evans CY; McGovern J; Das R; Takhar M; Erho N; Alshalafa M; Davicioni E; Schaeffer EM; Jenkins RB; Ross AE; Karnes RJ; Den RB; Fazli L; Gregory PA; Gleave ME; Williams ED; Rennie PS; Buttyan R; Gunter JH; Selth LA; Russell PJ; Nelson CC; Hollier BG
Oncogene; 2017 Jun; 36(24):3417-3427. PubMed ID: 28092670
[TBL] [Abstract][Full Text] [Related]
17. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
Friedlander TW; Ngo VT; Dong H; Premasekharan G; Weinberg V; Doty S; Zhao Q; Gilbert EG; Ryan CJ; Chen WT; Paris PL
Int J Cancer; 2014 May; 134(10):2284-93. PubMed ID: 24166007
[TBL] [Abstract][Full Text] [Related]
18. EMT and MET: necessary or permissive for metastasis?
Jolly MK; Ware KE; Gilja S; Somarelli JA; Levine H
Mol Oncol; 2017 Jul; 11(7):755-769. PubMed ID: 28548345
[TBL] [Abstract][Full Text] [Related]
19. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness.
Liao TT; Yang MH
Mol Oncol; 2017 Jul; 11(7):792-804. PubMed ID: 28649800
[TBL] [Abstract][Full Text] [Related]
20. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
